Fondazione Istituto Italiano Di Tecnologia

Fondazione Istituto Italiano Di Technologia

Fondazione Per La Ricerca Sulla Fibrosi Cistica-on-lus

Instituto Giannina Gaslini

Istituto Giannina Gasiini

Fondazione Per La Ricerca Sulla Fibrosi Cristica—onlus

Istituto Giannina Gaslini

Paolo Di Fruscia

Fabio Bertozzi

Tiziano Bandiera

Loretta Ferrera

Emanuela Caci

Federico Sorana

Nicoletta Pedemonte

Luis Juan Vicente Galietta

Alejandra Rodriguez Gimeno

Francesco Berti

Angelo Mario Reggiani

Silvia Pontis

Francesca Giacomina

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.

Pyrazole derivatives for the treatment of cystic fibrosis

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities. 

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof:  It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.

Compounds and compositions for the treatment of cystic fibrosis

Pharmaceutical compounds are disclosed having a bicyclic-sulphonamide structure of Formula 1:  wherein R1 represents an unsubstituted or a substituted heteroaryl ring; R2, R3, R4, and R5 are independently selected from hydrogen, alkyl, hydroxyalkyl, and alkyl-O-alkyl, provided that either R2 and R3, or R4 and R5 are linked or taken together to form a bridge between the carbon atoms to which R2 and R3, or R4 and R5 respectively are directly linked, whereby the N-containing ring in Formula 1 is an azabicyclo moiety. The compounds and compositions including the compounds may be used in therapy as brain-cell-death protectants, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).

Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions

Heterocyclic derivatives for the treatment of cystic fibrosis

Growing community of inventors

Genoa, Italy

Paolo Di Fruscia